Business briefs: Celgene

Share this article:

Celgene's Pomalyst (pomalidomide), an oral treatment for relapsed and refractory multiple myeloma, was approved by the FDA this week. It is the second such treatment approved for the blood cancer in the past seven months with Onyx's Kyprolis (carfilzomib) approved last July. Approval was based on response rate while clinical benefit (i.e. survival, symptoms) has not been verified by regulators. The treatment will only be available to patients through a restricted distribution program, Pomalyst REMS. Analysts forecast Pomalyst sales to reach $1.1 billion in 2017.

Share this article:

Email Newsletters

More in Business Briefs

DOJ closes Brilinta investigation

AstraZeneca announced the end of the investigation Tuesday.

Doctors back unique biosimilar names

A host of doctors has asked FDA Commissioner Margaret Hamburg to back a naming convention that would require biologics and biosimilars to have different names.

Roche has no rights to Sovaldi, panel rules

Despite a collaboration with original Sovaldi owner Pharmasset in 2004, a panel ruled Roche has no rights to HCV treatment Sovaldi.